ES135 / Eusol Biotech - LARVOL DELTA

The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome (clinicaltrials.gov) - P=N/A | N=24 | Completed | Sponsor: Tri-Service General Hospital | Recruiting ➔ Completed

Trial completion • Musculoskeletal Pain

The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome (clinicaltrials.gov) - P=N/A | N=28 | Recruiting | Sponsor: Tri-Service General Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment open • Trial completion date • Trial primary completion date • Musculoskeletal Pain

The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome (clinicaltrials.gov) - P=N/A | N=28 | Not yet recruiting | Sponsor: Tri-Service General Hospital

New trial • Musculoskeletal Pain

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury (clinicaltrials.gov) - P3 | N=160 | Suspended | Sponsor: Eusol Biotech Co., Ltd. | Active, not recruiting ➔ Suspended

Trial suspension • CNS Disorders • Musculoskeletal Diseases • Orthopedics

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury (clinicaltrials.gov) - P3 | N=160 | Active, not recruiting | Sponsor: Eusol Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Musculoskeletal Diseases • Orthopedics

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury (clinicaltrials.gov) - P3; N=160; Recruiting; Sponsor: Eusol Biotech Co., Ltd.; Trial completion date: Dec 2024 ➔ Dec 2026; Trial primary completion date: Dec 2022 ➔ Dec 2024

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Complement-mediated Rare Disorders • Musculoskeletal Diseases • Orthopedics

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury (clinicaltrials.gov) - P3; N=160; Recruiting; Sponsor: Eusol Biotech Co., Ltd.; N=100 ➔ 160

Clinical • Enrollment change • CNS Disorders • Complement-mediated Rare Disorders • Musculoskeletal Diseases • Orthopedics